GE Healthcare invests in non-invasive continuous glucose monitoring with C8 Medisensors' light-spectroscopy device.
GE Healthcare invested an undisclosed amount into C8 Medisensors, a developer of non-invasive continuous glucose monitors for diabetic patients.
C8 aims to provide glucose monitoring that is "painless, accurate, continuous, noninvasive, and nonintrusive to your life," according to its website.
The San Jose, Calif.-based company's glucose monitors use light spectroscopy to measure blood glucose levels without the need for frequent finger pricks.
"C8's technology platform presents great promise for patients to avoid the discomfort of traditional invasive glucose monitoring," GE VP and chief technology officer Mike Harsh said in prepared remarks. "This investment aligns with our strategy to fund innovations focused on reducing cost, increasing patient access and improving quality in healthcare."
Diabetes will affect as many as 552 million people worldwide by 2030, or about 1 in 10 adults, according to GE.
No comments:
Post a Comment